Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies
Da-Wei Chen,Tian Kang,Xiu-Zhang Xu,Wen-Jie Xia,Xin Ye,Yong-Bin Wu,Yao-Ri Xu,Jing Liu,Hui Ren,Jing Deng,Yang-Kai Chen,Hao-Qiang Ding,Muhammad Aslam,Wioleta M. Zelek,B. Paul Morgan,Rick Kapur,Sentot Santoso,Yong-Shui Fu
DOI: https://doi.org/10.1172/jci.insight.165142
IF: 9.4958
2023-03-23
JCI Insight
Abstract:Anti-CD36 Abs have been suggested to induce transfusion-related acute lung injury (TRALI) upon blood transfusion, particularly in Asian populations. However, little is known about the pathological mechanism of anti-CD36 Ab–mediated TRALI, and potential therapies have not yet been identified. Here, we developed a murine model of anti-CD36 Ab–mediated TRALI to address these questions. Administration of mouse mAb against CD36 (mAb GZ1) or human anti-CD36 IgG, but not GZ1 F(ab′) 2 fragments, induced severe TRALI in Cd36 +/+ male mice. Predepletion of recipient monocytes or complement, but not neutrophils or platelets, prevented the development of murine TRALI. Moreover, plasma C5a levels after TRALI induction by anti-CD36 Abs increased more than 3-fold, implying a critical role of complement C5 activation in the mechanism of Fc-dependent anti-CD36–mediated TRALI. Administration of GZ1 F(ab′) 2 , antioxidant ( N -acetyl cysteine, NAC), or C5 blocker (mAb BB5.1) before TRALI induction completely protected mice from anti-CD36–mediated TRALI. Although no significant amelioration in TRALI was observed when mice were injected with GZ1 F(ab′) 2 after TRALI induction, significant improvement was achieved when mice were treated postinduction with NAC or anti-C5. Importantly, anti-C5 treatment completely rescued mice from TRALI, suggesting the potential role of existing anti-C5 drugs in the treatment of patients with TRALI caused by anti-CD36.
medicine, research & experimental